Summary:
The purpose of this study is to look at the safety and tolerability of multiple doses of ITI-007 when given to healthy older volunteers [Part I] and older patients with dementia [Part II]. The study will help determine how ITI-007 behaves inside the body and how the body responds to the study drug by looking at the pharmacokinetics (PK) and pharmacodynamics (PD) of ITI-007. Your participation is for Part II, patients with Dementia. The study involves 12 days inpatient stay and one follow up visit.
Qualified Participants Must:
• Be 65 years of age or older
•
Have a clinical diagnosis of dementia characterized by impaired intellectual functioning that interferes with normal activities and relationships
Qualified Participants May Receive:
Study procedures at no cost and compensation up to $3,875, depending upon the part of the study in which you participate.